Isomorphic Labs was founded in 2021, with a mission to transform drug discovery with the power of artificial intelligence. Led by AI pioneer Sir Demis Hassabis, our founding was built on the Nobel-winning AI breakthrough, AlphaFold. Together with Google DeepMind, we developed and released AlphaFold 3 in May 2024, a revolutionary AI model that can predict the structure and interactions of all of life’s molecules with unprecedented accuracy. Our interdisciplinary team of drug discovery experts and machine learning specialists has built a world-leading AI drug design engine comprising foundational AI models that are capable of working across multiple therapeutic areas and drug modalities. The company is continually innovating on model architecture and developing cutting-edge capabilities to advance drug design. Our breakthrough technology is creating a broad and ambitious drug design portfolio of partnered and wholly-owned internal programs.